滋肾化痰方对肿瘤骨转移患者血清BSP指数及生活质量的影响

发布时间：2018-11-15 14:36

【摘要】：目的:探讨滋肾化痰方联合唑来膦酸对肿瘤骨转移患者生活质量的改善及对血清BSP指数的影响。方法:采用前瞻性、随机对照研究方法,将60例肿瘤骨转移患者按照1:1随机分为中西医结合组和西药组。中西医结合组给予滋肾化痰方和唑来膦酸联合治疗,西药组单独给予唑来膦酸治疗。采用EORTCQLQ-SF-36生活质量调查问卷评分,检测血清BSP指数,对骨疼痛程度进行评分比较。结果:在躯体功能、角色功能、情绪功能、物理症状及整体健康状况方面评分中西医结合组比西药组下降明显,与西药组评分比较差异有统学计学意义(P0.05),中西医结合组血清BSP指数比西药组下降明显,两组比较差异有统学计学意义(P0.05)。中西医结合组疼痛缓解程度明显优于西药组,与西药组评分比较差异有统计学意义(P0.05)。结论:滋肾化痰方联合唑来膦酸具有明显改善骨转移癌患者生活质量、降低血清BSP指数、减轻骨疼痛程度的作用。
[Abstract]:Objective: to investigate the effect of Zishen Huatan recipe combined with zoledronic acid on quality of life and serum BSP index in patients with bone metastasis. Methods: according to 1:1, 60 patients with bone metastasis were randomly divided into two groups: the group of integrated Chinese and western medicine and the group of western medicine. Combined therapy of Zishen Huatan recipe and zoledronic acid was given in the integrated Chinese and western medicine group, and zoledronic acid alone in the western medicine group. The quality of life questionnaire (QOL) of EORTCQLQ-SF-36 was used to measure the serum BSP index and to compare the severity of bone pain. Results: the scores of somatic function, role function, emotional function, physical symptom and overall health status in the integrated Chinese and western medicine group were significantly lower than those in the western medicine group, and there was a significant difference between the scores of the traditional Chinese and western medicine group and that of the western medicine group (P0.05). The serum BSP index of the integrated Chinese and western medicine group was significantly lower than that of the western medicine group, and the difference between the two groups had statistical significance (P0.05). The pain relief degree of the integrated Chinese and western medicine group was significantly better than that of the western medicine group, and there was significant difference between the western medicine group and the western medicine group (P0.05). Conclusion: Zishen Huatan recipe combined with zoledronic acid can significantly improve the quality of life, reduce serum BSP index and alleviate bone pain in patients with metastatic bone cancer.
【作者单位】：河南中医药大学第三附属医院;济源市中医院;
【基金】：河南省科技攻关计划项目(152102310099)
【分类号】：R273

【相似文献】